Abstract:BACKGROUND: Neurocognitive functioning is an important construct in childhood cancer survivorship, given the potential neurotoxicity of central nervous system (CNS) diseases and treatments and the relevance for important functional outcomes in adulthood. However, within pediatric oncology cooperative groups there have been significant barriers to neurocognitive data collection that have historically resulted in incomplete data (<30% compliance), thereby limiting progress in understanding the neurocognitive functioning of survivors. This paper describes the development, feasibility, and potential efficacy of a brief neurocognitive battery to maximize collection of psychometrically robust neurocognitive data within a pediatric cooperative group. We hypothesized that a novel set of procedures could result in collection of data from over 80% of eligible children.PROCEDURE: A novel assessment battery (ALTE07C1) that evaluates a child's cognitive, social, emotional, and behavioral functioning was developed. It included measures that were psychometrically sound, normed, widely available, and could be administered by any licensed psychologist. The battery required approximately 1 hour of administration time. A data monitoring team was developed to ensure prompt data collection.RESULTS: Approximately 75% (105 of 140) of institutions with eligible patients opened ALTE07C1; 159 participants have been enrolled. The overall compliance rate for submission of neurocognitive data exceeded 90%.DISCUSSION: Our study supports the feasibility and potential efficacy of a brief neurocognitive battery and a data monitoring team to evaluate children participating in multi-site pediatric oncology trials. Future work will utilize ALTE07C1 as a primary or secondary endpoint for pediatric trials when there is risk for neurocognitive impairment.

PA-CRM: A Continuous Reassessment Method for Pediatric Phase I Oncology Trials with Concurrent Adult Trials.

Robust EM Continual Reassessment Method in Oncology Dose Finding

Bridging Continual Reassessment Method for Phase I Clinical Trials in Different Ethnic Populations

Incorporating Historical Information to Improve Phase I Clinical Trials

A Default Method to Specify Skeletons for Bayesian Model Averaging Continual Reassessment Method for Phase I Clinical Trials

The Randomized CRM: An Approach to Overcoming the Long-Memory Property of the CRM

Adaptive Dose Modification for Phase I Clinical Trials

Application of the patient-reported outcomes continual reassessment method to a phase I study of radiotherapy in endometrial cancer

Continual Reassessment and Related Dose-Finding Designs

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

Incorporating patient-reported outcomes in dose-finding clinical trials with continuous patient enrollment

Comparative Review of Novel Model‐assisted Designs for Phase I Clinical Trials

Using Data Augmentation to Facilitate Conduct of Phase I-Ii Clinical Trials with Delayed Outcomes

Comparison of continual reassessment method adopting different stopping rules

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

Comparative review of novel model-assisted designs for phase I clinical trials.

Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Lessons Learned from Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer.

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial

Implementation of multi-site neurocognitive assessments within a pediatric cooperative group: Can it be done?